Chief executive officer at AmyriAD Therapeutics.
The Complexities of Alzheimer Disease Treatment and Diagnosis in Clinical Trials: Sharon L. Rogers, PhD
The chief executive officer at AmyriAD Therapeutics discussed the limitations of clinical trials assessing potential disease-modifying therapies for Alzhiemer disease including the lack of a diverse patient population and nonthorough clinical assessments for diagnosis. [WATCH TIME: 6 minutes]
2 Clarke Drive Cranbury, NJ 08512